Key safety measures including adverse events.

<div><p>Background</p><p>The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of the...

Full description

Saved in:

Bibliographic Details
Main Author:	Anuja Dokras (8679261) (author)
Other Authors:	Christos Coutifaris (245252) (author), Alan T. Remaley (77852) (author), Nehal N. Mehta (4588483) (author), Martin P. Playford (3127800) (author), Allen R. Kunselman (12647707) (author), Christy C. Stetter (22806397) (author), William C. Dodson (3286893) (author), Richard S. Legro (8086748) (author)
Published:	2025
Subjects:	Medicine Pharmacology Biotechnology Cancer Infectious Diseases Computational Biology Mathematical Sciences not elsewhere classified Chemical Sciences not elsewhere classified main methodologic limitation fasting glucose levels ci [− 3 ci [− 264 body mass index ages ≥ 18 4 %) completed 000 mg ), ≥ 25 kg ≤ 48 kg ≤ 40 years statistically significant changes polycystic ovary syndrome combined hormonal contraceptives rotterdam criteria ). different treatment groups comparable across groups ci [− 0 − 71 [; xlink "> clinicaltrials using metformin alone study period whilst combined group dropped 01 ), bmi mc − 0 2 </ sup 01 ), xlink "> − 0 combined groups combined ). − 2 study period significant difference metabolic syndrome 5 years 49 kg 10 [; combined group black ). waist circumference treat analysis screening visit robust evidence primary outcome p </ metformin group mean change mean bmi mean age
Tags:	Add Tag No Tags, Be the first to tag this record!

Key safety measures including adverse events.

Similar Items